Interpretation of Hepatitis B Surface Antibody Levels

Understanding Anti-HBs Levels and Immunity

The Centers for Disease Control and Prevention recommends that Anti-HBs levels ≥10 mIU/mL (or ≥10 IU/L) are considered protective against HBV infection, as established by guidelines from the CDC and other health organizations 1
A patient with an Anti-HBs level of 0.53 IU/L has a significantly low level of immunity, indicating a lack of protection against HBV infection, according to the CDC and other health organizations 1, 2
The American Academy of Family Physicians suggests that a result pattern of low Anti-HBs levels, such as 0.53 IU/L, indicates that the patient has never been infected with HBV and has not been successfully vaccinated, based on guidelines from the CDC and other health organizations 3

The CDC recommends that patients with low Anti-HBs levels, such as 0.53 IU/L, are susceptible to HBV infection and should receive the complete hepatitis B vaccination series, according to guidelines from the CDC and other health organizations 3, 4
The American College of Physicians states that without adequate Anti-HBs levels, patients have no protection against potential HBV exposure, based on guidelines from the CDC and other health organizations 1
The patient's serologic pattern is consistent with a person who is either never vaccinated against hepatitis B, previously vaccinated but did not develop adequate antibody response, or previously vaccinated but antibody levels have waned below protective levels, according to the CDC and other health organizations 3, 4

The CDC recommends administering the complete hepatitis B vaccine series following the standard schedule (0, 1, and 6 months), with alternative accelerated schedules available, according to guidelines from the CDC and other health organizations 3
The American Academy of Pediatrics suggests that for adults, the standard dose is 20 μg per dose for Engerix-B or 10 μg per dose for Recombivax HB, based on guidelines from the CDC and other health organizations 3

The CDC recommends performing post-vaccination serologic testing 1-2 months after completing the vaccine series to confirm development of protective immunity (≥10 mIU/mL), according to guidelines from the CDC and other health organizations 4, 1

The Infectious Diseases Society of America suggests that if Anti-HBs remains <10 mIU/mL after primary series, administering a second complete 3-dose series is recommended, according to guidelines from the CDC and other health organizations 4, 5
The American College of Physicians recommends testing for Anti-HBs 1-2 months after completion of the second series, based on guidelines from the CDC and other health organizations 4

The Occupational Safety and Health Administration recommends that if the patient works in healthcare or has other occupational risks, post-vaccination testing is particularly important, according to guidelines from the CDC and other health organizations 4, 6
The CDC suggests that for healthcare personnel with documented vaccination but unknown antibody response, testing for Anti-HBs upon hire is recommended; if <10 mIU/mL, providing one dose of HepB vaccine followed by Anti-HBs testing is advised, based on guidelines from the CDC and other health organizations 4
The Infectious Diseases Society of America recommends that immunocompromised individuals may require higher vaccine doses or additional doses to achieve protective immunity, according to guidelines from the CDC and other health organizations 5

The American Academy of Family Physicians warns that confusing Anti-HBs with HBsAg can lead to incorrect assumptions about immunity, according to guidelines from the CDC and other health organizations 7
The CDC advises that assuming a low but detectable Anti-HBs level provides any protection is incorrect; levels must be ≥10 mIU/mL to be considered protective, based on guidelines from the CDC and other health organizations 1, 2